How did patients with relapsed or refractory multiple myeloma (RRMM) respond to treatment with XPOVIO® (selinexor) + dexamethasone?

    In the clinical trial, 122 adults with RRMM were treated with XPOVIO 80 mg + dexamethasone 20 mg on Days 1 and 3 of every week. The approval was based upon results in a subgroup of 83 patients who no longer responded to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab.

    Clinical study results with XPOVIO + dexamethasone

    Group Created with Sketch. responded to treatment with XPOVIO + dexamethasone 1 in 4 patients

    1 in 4 patients

    responded to treatment
    with XPOVIO + dexamethasone

    In the clinical trial, patients took XPOVIO + dexamethasone for a median of 8 weeks, with some as long as 60 weeks.